Ravelcare Ltd

Dematerialization/Rematerialization status

• No requests for dematerialization or rematerialization of shares were received during 01 Jul 2026 to 30 Sep 2026.

Ravelcare Limited trading window closed from Thursday, October 01, 2026 till 48 hours after declaration of the Unaudited Financial Results for the half year ended September 30, 2026 (both days inclusive).

AGM Details

• AGM held on 23 September 2026 via VC/OAVM.
• Record date for voting: 16 September 2026.
• Remote e-voting window: 20–22 September 2026; voting at AGM via VC/OAVM.

Key Resolutions

• Resolution 1: adopt Audited Financial Statements for year ended 31 March 2026.
• Resolution 2: re-appoint Anita Varma by rotation.
• Resolution 3: re-appoint Ayush Varma as Managing Director.
• Resolution 4: re-appoint Maheshkumar Varma as Whole-time Director.

Voting Results

• Resolution 1 passed with requisite majority.
• Resolution 2 passed with requisite majority.
• Resolution 3 passed with requisite majority.
• Resolution 4 passed with requisite majority.

Directors / Management Changes

• Anita Varma re-appointed by rotation as director.
• Ayush Varma re-appointed as Managing Director.
• Maheshkumar Varma re-appointed as Whole-time Director.

AGM details

• AGM held on Sep 23, 2026, 11:30–11:50 a.m., via VC/OAVM.
• Chaired by Ayush Mahesh Varma, Chairman and MD.
• E-voting window: Sep 20–22, 2026; facility available during AGM.
• Auditors reported no qualifications.

Resolutions

• Ordinary: adopt audited financial statements for year ended Mar 31, 2026.
• Ordinary: re-appoint Anita Mahesh Varma (retiring by rotation).
• Special: re-appoint Ayush Varma as Managing Director.
• Special: re-appoint Maheshkumar Varma as Whole-time Director.

Voting and governance

• Voting results will be submitted separately.
• Scrutinizer appointed: CS Vishal Thawani of VTSN and Associates LLP.

Financial highlights

• Revenue from operations ₹2,695.43 Lakhs; up 7.9% YoY.
• PAT ₹515.40 Lakhs; net margin 19.1%.
• EBITDA ₹714.36 Lakhs; debt-free; net worth ₹3,740.84 Lakhs.

Growth & product strategy

• Ravel PRO launched June 2026; actives-led clinical haircare; listed on marketplaces; offline retail next.
• Derm-grade skincare range under development; launch by year-end.
• 27,000+ pincodes; 600,000+ customers; 35%+ repeat purchases.

IPO & capital structure

• IPO: Fresh issue 18.54 Lakh shares at ₹130; listing on BSE SME 8 Dec 2025; debut ₹201.
• Authorized capital raised to ₹7.01 Cr; paid-up ₹6.859 Cr; 68.59 Lakh shares listed.
• IPO proceeds utilised ₹760.91 Lakhs; unutilised ₹1,649.29 Lakhs; parked in Kotak Bank deposits.

Governance

• Ajinkya Jain resigned as Independent Director on 16-Jun-2026.
• Shruti Rajesh Sohane appointed Independent Director for 5 years from 16-Jun-2026.
• Alpesh Bhatt appointed Company Secretary & Compliance Officer on 17-Mar-2026.

Dividend & CSR

• No dividend proposed for FY2025-26.
• CSR spend ₹9.60 Lakhs; 2% of average net profit ₹9.53 Lakhs; excess ₹0.07 Lakhs; no unspent CSR funds.
• CSR policy on website; CSR Committee met twice (16 Jun 2025; 17 Mar 2026).

Audits & compliance

• Statutory Auditor: M/s Ratan Chandak & Co LLP; appointed 2024 AGM; unqualified report.
• Secretarial Auditor: M/s VTSN & Associates LLP; no qualifications.
• Internal controls adequate; no fraud reported; paperless communications.

Outlook & risks

• FY27 strategy: aggressive acquisition, scale Ravel PRO, derm-grade skincare, creator-led branding.
• Risks: rising digital ad costs, platform dependence, input costs, regulatory changes.
• Outlook: premiumisation supports cross-sell and higher lifetime value.

Product launches and strategy

• Ravel PRO launched on top e-commerce and quick-commerce platforms.
• AI-led diagnostic skincare range planned for H2 FY27 launch.
• PRO includes 12 products across five concerns: hair fall, growth, dandruff, damage, grey.
• PRO contributed ~20% incremental revenue in July 2026; first full month.

Financial performance

• FY26 revenue Rs 2,695.43 lakhs, up 7.9%.
• PAT Rs 515.40 lakhs; no debt; net worth Rs 3,740.84 lakhs.
• IPO raised Rs 2,410.20 lakhs in Dec 2025 (net Rs 2,191.10 lakhs).
• Forecast: FY27 growth supported by PRO scaling and skincare launches.

Backwards integration and outlook

• IPO proceeds allocated to manufacturing unit; funds unutilised and in fixed deposits.
• Two more PRO products launching in Sept; skincare range in H2 FY27.
• Management targets transformational growth in FY27 and beyond.

Change in Registered Office Address

• Previous registered office: 126, Neo Corporate Plaza, Cabin B, Ramchandra Lane Extension, Malad West, Mumbai 400064, Maharashtra, India.
• New registered office: 12th Floor, Flat 1211, 9 Business Bay, Mindspace, Malad (W), Mumbai-400064, Maharashtra, India
• Effective from August 26, 2026
• Within Mumbai city and Maharashtra state (same jurisdiction, ROC Mumbai)
• Board approved the shift of registered office
• Board approval obtained; no shareholder or regulatory approvals noted
• No explicit impact on operations or investor correspondence disclosed

Dematerialisation status

• Details of dematerialised/rematerialised securities for the period have been furnished to all stock exchanges.